 |
 |

Progressive Brain Volume Changes and the Clinical Course of Schizophrenia in Men
A Longitudinal Magnetic Resonance Imaging Study
Daniel H. Mathalon, PhD, MD;
Edith V. Sullivan, PhD;
Kelvin O. Lim, MD;
Adolf Pfefferbaum, MD
Arch Gen Psychiatry. 2001;58:148-157.
ABSTRACT
 |  |
Background We sought to determine whether the brain dysmorphology previously observed
cross-sectionally in people with schizophrenia progresses over time and whether
such progression is related to the severity of the illness course.
Subjects and Methods Men with chronic schizophrenia (n = 24) and control men (n = 25) received
2 brain magnetic resonance imaging scans, on average 4 years apart. Changes
in brain volume were adjusted for head-repositioning error and expressed as
slopes (cubic centimeters per year). Clinical course severity for the schizophrenic
patients was assessed using the mean of time 1 and time 2 Brief Psychiatric
Rating Scale (BPRS) scores and the percentage of time the patient was hospitalized
during the interscan interval.
Results Schizophrenic patients exhibited faster volume decline than control
subjects in right frontal gray matter and bilateral posterior superior temporal
gray matter, as well as faster cerebrospinal fluid volume expansion in right
frontal sulci, left lateral ventricle, and bilateral prefrontal and posterior
superior temporal sulci. Faster rates of frontal sulcal expansion were related
to greater BPRS total and positive symptom scores and longer time hospitalized.
Prefrontal gray matter decline and sulcal expansion were associated with greater
BPRS negative symptom scores and longer time hospitalized. Temporal lobe gray
matter decline was associated with greater BPRS total and negative symptom
scores.
Conclusions This controlled study revealed that patients with chronic schizophrenia
exhibited accelerated frontotemporal cortical gray matter decline and cortical
sulcal and lateral ventricular expansion. Further, greater clinical severity
was associated with faster rates of frontotemporal brain volume changes. These
observations are consistent with a progressive pathophysiological process
but need to be replicated in a larger sample.
INTRODUCTION
NEUROIMAGING studies have established that schizophrenia is associated
with brain dysmorphology, including increased ventricular and sulcal cerebrospinal
fluid (CSF) volumes1 and volume deficits in
cortical gray matter (but not white matter), particularly in temporolimbic
and frontal lobes.2, 3 Absence of
correlation between these brain volume abnormalities and illness duration,2 as well as the presence of these abnormalities at illness
onset,4, 5, 6 support
the view that brain dysmorphology in schizophrenia reflects a neurodevelopmental
insult and may not be progressive.7
A neurodevelopmental insult, however, does not preclude a neurodegenerative
process. Whether schizophrenia produces progressive brain changes can be addressed
definitively only with longitudinal imaging studies. Early computed tomography
studies with a predominant focus on ventricular enlargement generally failed
to show progression in schizophrenia,8, 9, 10, 11, 12
with some exceptions.13, 14 More
recent longitudinal computed tomography and magnetic resonance imaging (MRI)
studies of the lateral ventricles have yielded equivocal results, with some
showing no progressive ventricular enlargement15, 16, 17, 18, 19
and others indicating trends20 or significant
progression,21 at least among subgroups of people
with schizophrenia. These subgroups include patients with first-episode,22, 23 chronic poor outcome,24
and childhood-onset schizophrenia.25, 26, 27
Recent longitudinal MRI studies of schizophrenia have examined progression
of total brain tissue15, 18, 22, 23, 25, 28
or specific brain regions including temporal16, 22, 23, 26, 28, 29
and frontal26, 28 lobes, hippocampus/amygdala
complex,22, 23, 27, 29
and basal ganglia.20, 22, 23, 25
In these studies, progressive volume loss was observed for whole-brain measures
in patients with first-episode schizophrenia,22, 23
for temporal lobes and hippocampi in childhood-onset26, 27, 29
and first-episode22, 28 schizophrenia,
and for frontal lobes in childhood-onset,26
first-episode, and chronic schizophrenia.28
Clinical severity and course measures including time hospitalized,9, 10, 12, 16, 24
baseline and/or follow-up symptom ratings,10, 16, 18, 19, 24, 25, 26, 28, 29
and symptom change24, 28 have been
related to longitudinal brain volume changes in patients with schizophrenia,
with mixed results. Longer time hospitalized during the interscan interval9, 16, 24 or since illness onset10, 19 predicted slower ventricular enlargement
in first-episode schizophrenia,16 faster ventricular
enlargement in chronic schizophrenia,24 or no
significant brain changes.9, 10, 12
In first-episode schizophrenia, duration of initial untreated psychosis predicted
right temporal lobe volume decline,23 and an
unremitting course predicted greater ventricular expansion and cortical tissue
decline.18 In chronic schizophrenia, a poor
functional outcome predicted faster ventricular enlargement.24
In childhood-onset schizophrenia, greater severity at baseline and follow-up
predicted greater ventricular enlargement25
and right posterior superior temporal gyrus volume decline,29
and greater baseline severity also predicted faster decline of frontal, temporal,
and parietal gray matter.26 Considering symptom
changes between scans,28 declines in frontal
and temporal lobe volumes were associated with general symptom improvement
in chronic patients, and with improvement in delusions and thought disorder
but worsening of negative symptoms in first-episode schizophrenia. Thus, brain
volume decline in schizophrenic patients may be directly related to both clinical
severity and clinical improvement, underscoring the conceptual distinction
between course severity and symptom change over time.
Limitations of prior longitudinal imaging studies of schizophrenia include
small sample size; control groups that were absent,8, 9, 10, 11, 12, 17
small,16, 21, 22 or not
matched by age24; use of difference scores rather
than slopes when interscan intervals differed between subjects8, 24, 28;
and lack of control for head-repositioning error. Furthermore, few longitudinal
MRI studies26 have reported regional brain volume
changes specific to gray matter.
Previously we reported both widespread cortical gray matter volume deficits,
particularly in prefrontal and temporal regions, as well as sulcal and ventricular
enlargement in patients with chronic schizophrenia as compared with controls.30 Here we report brain volume change rates in a subgroup
of these patients, scanned twice over an average interval of 4 years, and
compare them with the normal aging changes observed in controls rescanned
at comparable intervals.31 A current theory
holds that the pathophysiology of schizophrenia involves a progressive or
neurodegenerative process.32, 33
This position derives from observations of progressive changes in symptoms
and decline in level of functioning during the illness course, 34
and longitudinal MRI data documenting accelerated brain volume changes in
people with schizophrenia.33, 35, 36
Based on this theoretical perspective and accumulating supportive evidence,
we hypothesized that patients with schizophrenia, relative to normal controls,
would exhibit faster cortical gray matter volume decline and sulcal expansion
in the frontal and temporal lobes as well as faster expansion of the lateral
ventricles. In light of previous observations that the duration of untreated
psychotic symptoms in schizophrenic patients predicts clinical deterioration
and poor treatment response,37, 38
we further hypothesized that patients with a more severe clinical course during
the interscan interval, defined by higher positive, negative, and total symptom
ratings at both scans and greater time hospitalized, would exhibit faster
frontotemporal brain volume decline.
SUBJECTS AND METHODS
SUBJECTS
All participants and/or legal guardians provided written informed consent.
Subjects (Table 1) were drawn from
a group of 71 men with schizophrenia and 73 control men described previously.30 For patients, repeat scans were obtained 7 months
to 7.5 years (mean = 3.6 years; median = 3 years) after initial MRI during
subsequent rehospitalizations or outpatient visits; for control subjects,
repeat scans were obtained 7 months to 6.7 years (mean = 4.2 years; median
= 5 years) after initial MRI.31
|
|
|
|
Table 1. Mean Demographic, Clinical, and Intracranial Volume Measures
in Controls and Schizophrenic Patients*
|
|
|
Patients (n = 24) were recruited from inpatient units of the VA Palo
Alto Health Care System (VAPAHCS) in Palo Alto, Calif, screened, and diagnosed
as previously described.30 At the time of each
scan, patients were taking antipsychotic medication and met DSM-III-R criteria for schizophrenia, determined by consensus of a
psychiatrist or psychologist conducting a semistructured interview and a trained
research assistant administering the Structured Clinical Interview for DSM-III-R (SCID).39 Exclusion
criteria were current alcohol or drug abuse or past history of dependence
(determined by the DSM-III-R), of significant medical
illness, or of head injury with loss of consciousness for more than 30 minutes.
After scan 1, most patients continued treatment with the VAPAHCS, but neither
clinical assessments nor medication dose or compliance data were systematically
recorded. Illness duration and onset age were estimated from SCID interviews
at each scan (Table 1).
Controls (n = 25) were recruited from the community for cross-sectional
normal aging40 or clinical studies.30, 41 Medical screening excluded subjects
with conditions potentially affecting brain morphology. Psychiatric screening
with the Schedule for Affective Disorders and SchizophreniaLifetime42 excluded subjects if they had ever met Research Diagnostic
Criteria43 for any psychiatric disorder or for
a substance abuse disorder in the year prior to study entry, had consumed
over 54 g of ethanol per day (4 "drinks" containing an average of 13.6 g of
ethanol) for more than 1 month, or scored less than 24 out of 30 on the Mini-Mental
State Examination.44 Original control subjects
were retested after varying intervals for additional studies31;
men were selected to generate a control group comparable to the patient group
in age, handedness,45 and interscan interval.
Patients and control subjects did not differ on premorbid IQ based on the
National Adult Reading Test,46 but the control
subjects had more education (Table 1).
SEVERITY OF CLINICAL COURSE
Two trained raters administered the Brief Psychiatric Rating Scale (BPRS)47 during a semistructured interview within 12 days of
each scan, and their ratings were averaged. Total scores, as well as positive
symptom (conceptual disorganization, unusual thought content, hallucinatory
behavior) and negative symptom (emotional withdrawal, motor retardation, blunted
affect) subscales,48 were used in the present
analysis. One patient did not have a BPRS rating at scan 2, so the closest
rating (22 months after scan 1 and 15 months before scan 2) was substituted.
Clinical severity during the interscan interval was assessed using the
mean of scan 1 and scan 2 BPRS ratings, as well as percentage of time the
patient was hospitalized in Department of Veterans Affairs (VA) facilities
during that interval. On average, patients were hospitalized 4 times (SD =
3.1) for a total of 203 days (SD = 172), representing 14.8% ± 8.3%
of the interscan interval. One patient hospitalized throughout his interscan
interval of 277 days (hospitalized 100% of the time) was excluded from this
analysis as a statistical outlier.
MAGNETIC RESONANCE IMAGING
Acquisition and Analysis
Baseline and follow-up scans used the same MRI protocol40
(1.5T General Electric Signa scanner, Milwaukee, Wis; axial spin echo, 5 mm
thick, 2.5 mm skip; field of view = 24 cm; 256 x 256 matrix; TE = 20,
80 milliseconds; cardiac cycle gated effective TR >2400 milliseconds; 256
phase encodes; oblique plane perpendicular to sagittal plane crossing through
anterior and posterior commissures).
Images were processed blind to subject identity. The most inferior MRI
slice used in quantification was identified as the index slice and was located
above the orbits, where anterior horns of the lateral ventricles appeared
bilaterally. Index slices for baseline and follow-up MRI were reviewed for
comparability across scans. The index slice and the 6 consecutive slices superior
to it sampled approximately half the brain and comprised our measure of intracranial
volume (ICV). Each slice was segmented into CSF, gray matter, and white matter
using a semiautomated segmentation algorithm.49
The regions of interest (ROIs) were a measure of lateral ventricles (CSF in
the inner 55% of all slices displaying ventricles) in addition to 2 frontal
and 2 temporal lobe regions, defined by divisions of the outer 45% of each
slice according to anatomical landmarks and a priori geometric rules: prefrontal,
frontal, anterior superior temporal, and posterior superior temporal (Figure 1). These ROIs did not encompass the
full volume of the lobes after which they were named but represented a large
sample of those cortical regions.
|
|
|
|
Figure 1. Seven axial magnetic resonance
images segmented into gray matter (dark gray), white matter (white), and cerebrospinal
fluid (black). The curved white lines mark the division of each section into
the outer 45% for cortical measures and inner 55% for ventricular measures.
Horizontal white lines mark 3 coronal planes used to delineate 4 quadrants
for defining cortical regions of interest. These planes pass through the most
anterior extreme of the genu of the corpus callosum, the most posterior extreme
of the splenium of the corpus callosum, and midway between them. Six cortical
regional measures are defined by summing quadrants across slices as follows:
a = prefrontal; b = frontal; c = anterior superior temporal; d = posterior
superior temporal; e = anterior superior parietal; and f = posterior parietal-occipital.
The present study employs only the prefrontal, frontal, and anterior and posterior
temporal cortical regions, and the lateral ventricles.
|
|
|
Volume Change
Observed ROI volume differences (in cubic centimeters) between scans
represents true biological change over time, plus measurement error primarily
due to head-positioning differences in the scanner. A change in ICV from scan
1 to scan 2 (Table 1) was considered
an index of longitudinal measurement error because presumably an adult's head
size does not change between scans. The range in correlations between ROI
and ICV change scores was 0.08 to 0.47. We adjusted for this error using linear
regression,31, 50, 51
in which each ROI change score is regressed on ICV change and a dummy variable
coding group. Resulting residual scores represented ROI volume changes independent
of ICV change and, after adding back the appropriate group intercept, provided
an ROI volume change score adjusted for longitudinal measurement error. Adjusted
ROI change scores were divided by interscan interval to control for interval
variation between subjects, yielding adjusted slopes (cubic centimeters per
year) as the units for all subsequent longitudinal MRI volume analyses.
STATISTICAL ANALYSIS
To determine whether brain changes progressed faster in patients with
schizophrenia than in normal control subjects, left and right hemisphere-adjusted
ROI slopes were analyzed using 2-way (group x hemisphere) repeated-measures
analysis of variance (ANOVA). In addition, 2-way (group x hemisphere)
analysis of covariance (ANCOVA) was performed for each ROI to control for
potential confounding effects of age and National Adult Reading Test premorbid
IQ. Pearson correlations assessed the relationships of clinical severity with
ROI slopes. Between-group effect sizes for group differences are reported
in the tabled results, and 2-tailed probability values are reported for the
statistical tests ( = .05) of our main hypotheses. In addition, because
we had no a priori predictions about correlations emerging for ROIs in only
1 hemisphere, exploratory correlational analyses examined relationships between
the clinical severity measures and the ROI slopes for each hemisphere separately
(setting = .01).
RESULTS
Scans were acquired between 1989 and 1996. Scan 1 dates were distributed
over a broader calendar range in patients than in control subjects, but scan
2 dates were similarly distributed across both groups. Interscan intervals
were not significantly different between the groups (t47 = 0.94, P = .35). Intracranial volume decreased
similarly in both groups between scan 1 and scan 2 (Table 1; controls by 1%, patients by 2%; t47 = 1.22, P = .23), reflecting both head-repositioning
artifacts and uncontrolled aspects of the scanning procedure and providing
an estimate of longitudinal method error used to statistically adjust the
ROI change scores. Test-retest reliability of the ICV estimates across the
2 study scans, assessed with intraclass correlations52
of all scan 1 and scan 2 data, was 0.92 in the patients and 0.94 in the controls.
Schizophrenic patients had significantly lower BPRS total scores at scan 2
than at scan 1 (t23 = -2.99, P = .007), reflecting the fact that all patients were hospitalized
at scan 1, but many were outpatients at scan 2.
GROUP DIFFERENCES IN RATES OF CHANGE OF REGIONAL BRAIN VOLUMES
Analysis of mean MRI slopes for the 9 ROIs (Table 2), based on 2-way (group x hemisphere) repeated-measures
ANOVA, showed a significant group effect for posterior temporal sulci and
group trends for posterior temporal gray matter and prefrontal sulci (Figure 2). Mean between-group effect sizes
across hemispheres were in the range of 0.42 to 0.51 (Table 2), all indicating faster progression in the schizophrenic
patients than in control subjects. Additional group differences in ROI slopes
depended on hemisphere, with significant group x hemisphere interactions
emerging for frontal sulci and gray matter and for the lateral ventricles.
For the frontal region, relative to the control subjects, schizophrenic patients
showed faster sulcal expansion and gray matter decline in the right but not
the left hemisphere (Figure 2). Between-group
effect sizes for the right frontal region were 0.58 for sulci and 0.60 for
gray matter (Table 2). Lateral
ventricular expansion was faster in schizophrenic patients than in control
subjects, and this expansion was significantly faster in the left than in
the right hemisphere (Figure 2).
A trend toward a group x hemisphere interaction for prefrontal gray
matter indicated that schizophrenic patients have faster gray matter decline
on the right side than control subjects but, contrary to our directional hypothesis,
that controls have faster decline on the left than the patients.
|
|
|
|
Table 2. Adjusted Magnetic Resonance Imaging Slopes for Normal Controls
and Schizophrenic Patients: Means, Percent Change per Year, and Effect Sizes*
|
|
|
|
|
|
|
Figure 2. Means and distributions of left
and right hemisphere magnetic resonance imaging slopes (cubic centimeters
per year) for regions of interest in which patients with schizophrenia (SZ)
exhibited significant bilateral or unilateral progression relative to normal
control men (NC). Means are represented by solid horizontal lines drawn on
each group's distribution. In the right (but not the left) hemisphere, frontal
gray matter volume declined, and frontal sulcal cerebrospinal fluid expanded
faster in the schizophrenic patients than in the control subjects. On the
left (but not the right), lateral ventricular volume increased faster in the
schizophrenic patients than in controls. Prefrontal and posterior superior
temporal sulcal cerebrospinal fluid volume expanded faster and posterior superior
temporal gray matter declined faster in the schizophrenic patients than in
controls, bilaterally.
|
|
|
Neither age at scan 1 nor National Adult Reading Test IQ significantly
differed between the groups (Table 1),
nor did these variables significantly correlate with any ROI slopes within
each group. Two-way ANCOVA, separately controlling for each of these variables,
yielded essentially the same ROI results as the ANOVA. In addition, significant
group differences in ROI slopes persisted after controlling for baseline ROI
volumes using ANCOVA. These group differences emerged despite considerable
overlap between the group distributions of ROI slopes and evidence of greater
variability in the patients than in control subjects (Figure 2).
RELATIONSHIPS OF ROI SLOPES WITH CLINICAL SEVERITY MEASURES
Clinical symptom severity, as reflected by time-averaged BPRS ratings
and percentage of time hospitalized during the interscan interval, was significantly
correlated with the rate of progressive volume changes in frontotemporal regions
of schizophrenic patients (Table 3
and Figure 3). In terms of global
measures of severity, higher BPRS total scores were related to faster frontal
sulcal expansion and anterior temporal lobe gray matter decline, accounting
for 35% and 21% of the variance in these ROI slopes, respectively. Percentage
of time hospitalized accounted for 27% of the variance in prefrontal sulcal
expansion and gray matter decline, and 23% of the variance in frontal sulcal
expansion. In terms of specific symptom domains, higher BPRS positive symptom
scores were associated with faster frontal sulcal expansion, accounting for
36% of the variance. Higher negative symptom scores were associated with faster
prefrontal sulcal expansion and gray matter decline, accounting for 14% and
25% of their variances, respectively, and also accounted for 18% of the variance
in posterior temporal lobe gray matter decline. Percentage of time hospitalized
and time-averaged BPRS scores were not significantly correlated, indicating
their sensitivity to distinct aspects of clinical severity.
|
|
|
|
Table 3. Pearson Correlations of MRI Slopes With Clinical Severity
Measures in Schizophrenic Patients*
|
|
|
|
|
|
|
Figure 3. Scatterplots depicting significant
correlations between magnetic resonance imaging slopes (cubic centimeters
per year) and mean Brief Psychiatric Rating Scale (BPRS) scores (mean of baseline
and follow-up ratings) and percentage of time hospitalized in schizophrenic
patients. In general, patients who exhibited more severe clinical symptoms
at baseline and follow-up and who spent a greater proportion of the interscan
interval hospitalized showed faster rates of regional cortical gray matter
volume decline and sulcal cerebrospinal fluid expansion.
|
|
|
Supplementing the correlations based on bilateral ROI slopes, analyses
of the separate left and right hemisphere ROIs identified 2 additional correlations.
Higher BPRS positive symptom scores correlated with faster decline of left
frontal gray matter (r = -0.50, P = .01), consistent with their association with faster bilateral frontal
sulcal expansion. Higher BPRS negative symptom scores correlated with faster
right frontal sulcal expansion (r = 0.54, P = .006).
COMMENT
These longitudinal MRI data, obtained over an average interval of 4
years, provide support for progressive brain volume changes in patients with
chronic schizophrenia that exceed the normal aging changes observed in healthy
control subjects. Although some differences were small, 14 of the 18 regions
examined showed faster progression in the patients than in controls. Further,
when significant group differences did emerge, they were generally in the
predicted direction, with schizophrenic patients progressing faster than normal
control subjects. The faster brain volume changes in the patients with schizophrenia
were not always evident bilaterally, nor was a single hemisphere consistently
implicated. Rather, a pattern of volume progression was evident in right frontal
gray matter and sulci, bilateral posterior temporal sulci, and the left lateral
ventricle, with trends in the bilateral posterior temporal gray matter and
prefrontal sulci. This pattern corroborated results from a previous longitudinal
study of first-episode schizophrenia,22 in which
patients showed faster bilateral temporal lobe volume loss and left lateral
ventricular expansion than control subjects during a 4-year interval. Moreover,
our finding that patients exhibited faster left ventricular expansion is consistent
with several previous longitudinal reports based on first-episode,22, 23 childhood-onset,25
and chronic poor outcome24 schizophrenia as
well as with prior cross-sectional studies,53, 54
suggesting that a progressive process may disproportionately affect left subcortical
structures.
The progressive volume changes in temporal and frontal lobes observed
in the schizophrenic patients are striking in light of cross-sectional MRI
studies showing particularly prominent volume deficits in these regions.30 Decline in temporal lobe tissue or gray matter was
observed in patients with childhood-onset26, 29
and first-episode22 schizophrenia. A recent
MRI study28 did not find faster temporal volume
decline in chronic or first-episode patients; however, measurement of undifferentiated
tissue may have obscured volume decline specific to gray matter. The frontal
gray matter decline and sulcal expansion are consistent with previous longitudinal
observations of frontal tissue decline in people with schizophrenia,28 including patients with childhood-onset schizophrenia.26 Assuming an ex vacuo process,
we would have expected the observed prefrontal sulcal expansion in patients
to be accompanied by prefrontal gray matter decline. Perhaps sulcal CSF volume
is more sensitive to diffuse tissue loss than to tissue volume itself because
additive ex vacuo effects of small distributed tissue
losses may accumulate in sulcal CSF. Whether underlying white matter changes
contribute to prefrontal sulcal expansion over time is unclear, but previously
we have not found white matter volume deficits in patients with schizophrenia.30, 55 However, other aspects of white matter
integrity may be compromised in schizophrenia.56, 57
A more severe clinical course, as measured by time-averaged BPRS total,
positive, and negative symptom scores as well as percentage of time hospitalized,
was associated with faster frontal and temporal lobe rates of progression,
further corroborating the pathophysiological significance of accelerated progressive
changes observed in the patients. Moreover, the correlations are consistent
with models linking positive and negative symptoms to dysfunctional frontotemporal
circuitry.58, 59, 60, 61, 62, 63, 64, 65
Positive symptom severity correlated with indicants of faster deterioration
in the frontal lobes, whereas negative symptom severity correlated with indicants
of faster deterioration in the prefrontal, frontal, and posterior temporal
lobes, particularly in terms of cortical gray matter volume decline. The more
global measures of clinical severity were also associated with faster progressive
brain changes, with higher BPRS total scores correlated with faster frontal
sulcal expansion and anterior temporal lobe gray matter decline, and percentage
of time hospitalized correlated with faster prefrontal and frontal sulcal
expansion and faster prefrontal gray matter decline. Similar brain volume
change relationships with clinical severity were reported based on time hospitalized,24 clinical ratings,25, 29
or other measures.18, 23, 24
Overall, the results of the present study indicated that progressive brain
volume changes were greater in schizophrenic patients with more severe symptoms
at both scans, suggesting that persistent or cumulative clinical severity
reflects progressive pathophysiological processes.
Brain changes associated with greater severity could reflect medication-induced
neurotoxicity, because patients with more severe symptoms tend to receive
higher doses of antipsychotic medication. Alternatively, psychosis itself
may be neurotoxic,37, 66 such that
noncompliance with or nonresponsiveness to neuroleptics may contribute to
faster brain volume decline in symptomatic patients. Unfortunately, medication
history and compliance data were not systematically recorded, precluding resolution
of this issue in our study. Evidence that antipsychotic medication may be
"neuroprotective" derives from longitudinal imaging studies (medication compliance
is associated with less ventricular expansion21, 23
and less temporal lobe volume decline23), first-episode
follow-up studies (early antipsychotic treatment improves clinical outcome67, 68), and animal studies (certain antipsychotics
block neurotoxic effects of psychotogenic N-methyl
D-aspartate antagonists65). However, higher
medication doses in patients with first-episode schizophrenia have been associated
with greater frontal and temporal lobe volume decline,28
which could have resulted from medication- or psychosis-related neurotoxicity.
Several studies found no correlation between medication and brain changes
over time.10, 19, 22 Thus,
the hypothesis that psychosis is neurotoxic and that medication is neuroprotective
remains speculative.
The present data suggest that neurodegenerative processes operate during
the course of schizophrenia and that brain volume deficits are not simply
static manifestations of anomalous neurodevelopment.69, 70
A principal argument against a neurodegenerative pathophysiology in schizophrenia
is the absence of gliosis in most71, 72, 73
but not all74, 75, 76
neuropathological studies; however, observations of gliosis depend on techniques
used, brain regions examined, and presence or absence of associated dementia.77 Furthermore, lack of gliosis by itself does not prove
that degenerative processes are absent in schizophrenia, because gliosis does
not always accompany neuronal injury76 and does
not occur in apoptosis,78, 79 a process
which could produce progressive neural tissue loss. In addition, neuropil
abnormalities observed in schizophrenia76, 80
involving axonal, dendritic, and synaptic organization and alterations in
neuronal size can occur throughout life. Excitatory amino acid neurotransmitters,
abnormalities of which have been implicated in schizophrenia,81, 82, 83
can produce excitotoxic cellular damage leading to dendritic neuropil reduction
and neuronal loss84 without gliosis.81 Thus, brain volume deficits in schizophrenia may result
from multiple pathophysiological processes, including anomalous neurodevelopment
and progressive neuronal injury, that do not produce neuropathological changes
typical of established neurodegenerative disorders.
This study has limitations. Our results can be generalized only to men.
Interscan interval variability may have contributed measurement error to volume
change estimates, which was not entirely remedied by employing slopes. The
MRI protocol used is coarse by current standards: acquisition of noncontiguous
slices precludes full voluming of brain regions, 7 axial slices covered only
half the brain, and ROIs were geometrically defined. However, the protocol
was retained for longitudinal study, provided a robust signal for tissue segmentation,
and proved sensitive to brain changes. Although measurement precision was
insufficient to express absolute volume change, relative differences between
patients and controls could be interpreted with confidence because measurement
error was similarly distributed across groups. Although we calculated slopes
to account for interscan interval variability, we make no assumption that
change is uniformly linear throughout the illness course. Accordingly, extrapolation
to periods beyond the interscan intervals represented is unwarranted. Clinical
assessments were limited because complexities of symptoms and illness during
the interscan interval cannot be fully characterized by BPRS ratings at only
2 time points. In addition, the results must be regarded as preliminary because
the sample sizes were relatively small for the number of statistical tests
performed. The validity of the present results will ultimately depend on their
replication in a larger sample.
The ascendance of the neurodevelopmental hypothesis notwithstanding,
several pieces of evidence suggest decline in cognitive, social, and occupational
function in people with schizophrenia, consistent with progressive pathophysiology.85, 86, 87, 88, 89, 90, 91, 92, 93
Kraepelin described a deteriorating course for many schizophrenic patients
and posited neurodegenerative processes.94 The
neurodegenerative hypothesis in schizophrenia has been overshadowed in recent
years by the neurodevelopmental hypothesis, and although they are sometimes
presented as mutually exclusive, a neurodevelopmental insult need not preclude
a neurodegenerative process.3, 63, 95
Indeed, the present study suggests that dismissal of neurodegenerative processes
in schizophrenia may be premature.
AUTHOR INFORMATION
Accepted for publication September 25, 2000.
Dr Mathalon is currently at the Department of Psychiatry, Yale University
School of Medicine, and Dr Lim is now at the Nathan Kline Institute.
This research was supported by grants MH58007, MH30854, AA05965, and
AA10723 from the National Institutes of Health, Bethesda, Md; and by the Department
of Veterans Affairs, Washington, DC.
Earlier reports of these data were presented at the International Congress
on Schizophrenia Research, Colorado Springs, Colo, April 12-16, 1997; the
Annual Meeting of the American College of Neuropsychopharmacology, Wai Koloa,
Hawaii, December 8-12, 1997, and Acapulco, Mexico, December 12-16, 1999; and
the Annual Meeting of the Society of Biological Psychiatry, Toronto, Ontario,
May 27-31, 1998, and Chicago, Ill, May 11-13, 2000.
We would like to thank the staff of the Laboratory of Physiological
and Structural Brain Imaging and Mental Health Clinical Research Center for
their patient care and invaluable assistance in conducting this research project.
In particular, we thank Brian Matsumoto, MA, for image analysis; Kenneth Chow,
MA, for data processing; and Margaret Rosenbloom for editorial assistance.
From the Department of Psychiatry and Behavioral Sciences, Stanford
University School of Medicine, Stanford, Calif (Drs Mathalon, Sullivan, and
Lim); the Psychiatry Service, VA Palo Alto Health Care System, Palo Alto,
Calif (Dr Lim); and the Neuropsychiatry Program, Center for Health Sciences,
SRI International, Menlo Park, Calif (Dr Pfefferbaum).
Corresponding author and reprints: Daniel H. Mathalon, PhD, MD, VA
Connecticut Healthcare System, Psychiatry Service 116A, 950 Campbell Ave,
West Haven, CT 06516 (e-mail: daniel.mathalon{at}yale.edu).
REFERENCES
 |  |
1. Shelton RC, Weinberger DR. X-ray computerized tomography studies in schizophrenia: a review and
synthesis. In: Nasrallah HA, Weinberger DR, eds. The Neurology
of Schizophrenia. Amsterdam, the Netherlands: Elsevier; 1986:207-250.
2. Marsh L, Lauriello J, Sullivan EV, Pfefferbaum A. Neuroimaging in neuropsychiatric disorders. In: Bigler E, ed. Neuroimaging II: Clinical Applications. New York, NY: Plenum Press; 1996:73-125.
3. Shenton M, Wible CG, McCarley RW. A review of magnetic resonance imaging studies of brain abnormalities
in schizophrenia. In: Krishnan KRR, Doraiswamy PM, eds. Brain Imaging
in Clinical Psychiatry. New York, NY: Marcel Dekker Inc; 1997:297-380.
4. Bogerts B, Ashtari M, Degreet G, Alvir JM, Bilder RM, Lieberman JA. Reduced temporal limbic structure volumes on magnetic resonance images
in first episode schizophrenia. Psychiatry Res. 1990;35:1-13.
ISI
| PUBMED
5. Lim KO, Tew W, Kushner M, Chow K, Matsumoto B, DeLisi LE. Cortical gray matter volume deficit in patients with first-episode
schizophrenia. Am J Psychiatry. 1996;153:1548-1553.
FREE FULL TEXT
6. Nopoulos P, Torres I, Flaum M, Andreasen NC, Ehrhardt JC, Yuh WTC. Brain morphology in first-episode schizophrenia. Am J Psychiatry. 1995;152:1721-1723.
FREE FULL TEXT
7. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660-669.
ABSTRACT
8. Hoffman WF, Ballard L, Turner EH, Casey DE. Three-year follow-up of older schizophrenics: extrapyramidal syndromes,
psychiatric symptoms, and ventricular brain ratio. Biol Psychiatry. 1991;30:913-926.
FULL TEXT
|
ISI
| PUBMED
9. Illowsky B, Juliano DM, Bigelow LB, Weinberger DR. Stability of CT scan findings in schizophrenia: results of an 8 year
follow-up study. J Neurol Neurosurg Psychiatry. 1988;51:209-213.
ABSTRACT
10. Nasrallah HA, Olson SC, McCalley-Whitters M, Chapman S, Jacoby CG. Cerebral ventricular enlargement in schizophrenia: a preliminary follow-up
study. Arch Gen Psychiatry. 1986;43:157-159.
ABSTRACT
11. Sponheim SR, Iacono WG, Beiser M. Stability of ventricular size after the onset of psychosis in schizophrenia. Psychiatry Res. 1991;40:21-30.
FULL TEXT
|
ISI
| PUBMED
12. Vita A, Sacchetti E, Valvassori G, Cazzullo CL. Brain morphology in schizophrenia: a 2- to 5-year CT scan follow-up
study. Acta Psychiatr Scand. 1988;78:618-621.
ISI
| PUBMED
13. Kemali D, Maj M, Galderisi S, Milici N, Salvati A. Ventricle-to-brain ratio in schizophrenia: a controlled follow-up study. Biol Psychiatry. 1989;26:753-756.
FULL TEXT
|
ISI
| PUBMED
14. Woods BT, Yurgelun-Todd D, Benes FM, Frankenburg FR, Pope HG, McSparren J. Progressive ventricular enlargement in schizophrenia: comparison to
bipolar affective disorder and correlation with clinica |